Strategic Partnership Leverage AstraZeneca linkage to accelerate global commercialization of ZS-9, including access to AZ's sales force, distribution, and payer networks to speed market entry and scale.

Specialist Targeting Target nephrology and cardiology practices managing hyperkalemia in chronic disease patients, focusing on RAASi-treated populations to position ZS-9 as a key adjunct therapy to prevent renal and cardiac complications.

Payer Formulary Engage payers and hospital formularies with evidence on reducing adverse events and hospitalizations from controlled potassium, supporting value-based pricing with backing from AZ.

Market Expansion Explore expansion to related patient groups with high hyperkalemia risk and consider partnerships to extend the ion-trap technology for additional assets.

Evidence Driven Leverage the robust clinical program to generate real world evidence and partner with academic centers and health systems to demonstrate outcomes, accelerating clinician adoption.